GleamWall
中文EN

RNAZ Transcode Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829635 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-435.7%
TTM EPS YoY81.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-866.1%
ROA-581.7%
ROIC (approx.)-909.8%
Asset turnover—

Leverage & solvency

Liabilities / assets28.2%
Debt / equity0.00x
Current ratio0.96x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-476.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.55M$3.69M$5.11M$5.48M$3.16M$2.57M$2.22M$3.64M
SG&A expense$3.76M$2.54M$2.22M$1.76M$1.40M$1.66M$951,652$1.45M
Operating income-$109.69M-$6.79M-$17.76M-$16.03M-$4.56M-$4.22M-$3.17M-$5.09M
Interest expense$6,979——$542$5,960$0$114$1,832
Pretax income-$107.70M-$6.75M-$17.55M-$13.22M-$4.86M-$4.28M-$12.09M—
Income tax———$226,069$0$0$0$0
Net income-$107.38M-$6.75M-$17.79M-$13.44M-$4.86M-$4.28M-$12.09M-$5.92M
EBITDA-$109.66M-$6.77M-$17.73M-$15.98M-$4.56M-$4.21M-$3.16M-$5.08M
EPS (basic)-9.36-7.17-21.28—-5.82-5.13-70.16—
EPS (diluted)-9.36-7.17-21.28—-5.82-5.13-70.16—
Weighted avg. shares (diluted)11.47M957,191916,968—833,683833,653172,262—
Balance sheet
Cash & equivalents$4.64M$8.38M$12.84M$17.81M$2.84M$7.37M$11.57M$5.81M
Current assets$6.70M$10.64M$16.75M$21.98M$4.75M$8.24M$13.04M$7.09M
PP&E, net$9,326$322,809$346,745$370,681$19,908$24,689$38,131$51,574
Goodwill$25.74M$25.74M$25.74M$25.74M————
Intangibles$12.30M$114.30M$114.30M$114.30M————
Total assets$44.75M$151.01M$157.16M$162.40M$5.23M$8.27M$13.19M$7.29M
Current liabilities$6.98M$5.40M$5.38M$3.49M$2.97M$1.56M$2.51M$2.77M
Total liabilities$12.61M$12.65M$12.64M$10.52M$3.80M$2.12M$2.90M$9.31M
Shareholders' equity$32.14M-$27.69M$1.25M$10.34M$1.43M$6.15M$10.29M-$2.02M
Shares outstanding17.24M1.01M916,968916,968833,683833,68323.34M36,753
Cash flow statement
Operating cash flow-$7.66M-$5.40M-$4.98M-$8.14M-$4.08M-$4.19M-$3.10M-$3.15M
Capital expenditure———————$500
Free cash flow———————-$3.15M
Investing cash flow———————-$500
Financing cash flow$3.92M——$23.12M-$455,726$0$8.85M$7.08M
Depreciation & amortization$21,812$23,937$23,936$44,780$4,781$13,443$13,443$10,346
Stock-based compensation$315,314——$61,865$134,324$131,510$157,729$168,770

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.